Clinical Laserthermia Systems announces that the last patient is treated in clinical study in the US
Lund, Sverige – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today announced via their US subsidiary, CLS Americas, that all twenty patients have been successfully treated within the Phase I clinical study titled, “Targeted MRI/US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer”.The study is being conducted by Urological Research Network, LLC, a Florida-based, not-for-profit clinical research organization. The study utilizes CLS’s TRANBERG® Thermal Therapy System in combination with the Focalyx® Fusion medical device for treatment